Aug. 19 at 12:08 PM
Piper Sandler🏁
$DAWN Overweight-
$25 and said, Investor sentiment has declined following the first two 2025 earnings reports given concern around the potential plateauing of Ojemda ~1 year into launch.
$RHHBY $NVS $PFE $BMY ALPMY
Piper Sandler additionally said in its
$DAWN initiation:
We think the stock move is overdone and that these early decelerations are simply artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies.
And while the growth may be more gradual that the Street originally expected, we continue to believe the clinical data will support strong penetration longer term.
